Davidson Trust Co. Has $3.70 Million Stake in Johnson & Johnson (NYSE:JNJ)

Davidson Trust Co. lowered its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 7.6% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 22,294 shares of the company's stock after selling 1,833 shares during the quarter. Johnson & Johnson makes up approximately 1.8% of Davidson Trust Co.'s holdings, making the stock its 12th largest position. Davidson Trust Co.'s holdings in Johnson & Johnson were worth $3,697,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in JNJ. Brighton Jones LLC raised its stake in Johnson & Johnson by 13.9% during the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company's stock valued at $7,502,000 after acquiring an additional 6,332 shares in the last quarter. Hudson Value Partners LLC raised its stake in Johnson & Johnson by 2.5% during the 4th quarter. Hudson Value Partners LLC now owns 41,403 shares of the company's stock valued at $5,648,000 after acquiring an additional 1,022 shares in the last quarter. Proficio Capital Partners LLC raised its stake in Johnson & Johnson by 22.0% during the 4th quarter. Proficio Capital Partners LLC now owns 19,951 shares of the company's stock valued at $2,885,000 after acquiring an additional 3,594 shares in the last quarter. Raymond James Financial Inc. bought a new stake in Johnson & Johnson during the 4th quarter valued at $1,339,878,000. Finally, E Fund Management Co. Ltd. raised its stake in Johnson & Johnson by 65.0% during the 4th quarter. E Fund Management Co. Ltd. now owns 28,376 shares of the company's stock valued at $4,104,000 after acquiring an additional 11,181 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company's stock.

Analyst Ratings Changes

A number of analysts have recently commented on JNJ shares. Royal Bank Of Canada reissued an "outperform" rating and issued a $181.00 price objective on shares of Johnson & Johnson in a research note on Thursday, June 5th. Benchmark raised Johnson & Johnson to a "strong-buy" rating in a research note on Thursday, April 24th. Raymond James Financial dropped their price objective on Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating on the stock in a research note on Monday, April 14th. Morgan Stanley boosted their price objective on Johnson & Johnson from $164.00 to $169.00 and gave the stock an "equal weight" rating in a research note on Wednesday, April 16th. Finally, Barclays dropped their price objective on Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating on the stock in a research note on Thursday, April 17th. Eleven investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat.com, Johnson & Johnson presently has a consensus rating of "Moderate Buy" and a consensus target price of $170.88.

Johnson & Johnson Stock Up 0.2%

Shares of NYSE JNJ traded up $0.34 during mid-day trading on Friday, hitting $155.90. The company had a trading volume of 3,482,521 shares, compared to its average volume of 8,059,757. The company has a market capitalization of $375.11 billion, a PE ratio of 17.34, a price-to-earnings-growth ratio of 2.36 and a beta of 0.41. The firm has a 50-day simple moving average of $153.68 and a two-hundred day simple moving average of $154.09. The company has a current ratio of 1.26, a quick ratio of 1.03 and a debt-to-equity ratio of 0.49. Johnson & Johnson has a one year low of $140.68 and a one year high of $169.99.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, beating the consensus estimate of $2.59 by $0.18. Johnson & Johnson had a return on equity of 33.46% and a net margin of 24.42%. The company had revenue of $21.89 billion during the quarter, compared to analysts' expectations of $21.65 billion. On average, equities analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th were paid a $1.30 dividend. This is a positive change from Johnson & Johnson's previous quarterly dividend of $1.24. The ex-dividend date of this dividend was Tuesday, May 27th. This represents a $5.20 annualized dividend and a yield of 3.34%. Johnson & Johnson's dividend payout ratio is currently 57.84%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.